Launching Veris™ – Disrupting Wound Care with Smart Honey Science

Joint Go-to-Market Plan | SweetBio × iuvoCare





Why This Matters Now

8M

Americans

Living with chronic wounds

$38B

Annual Cost

Direct costs for wound care in the US

2026

CMS Changes

Reimbursement headwinds intensifying

Veris™ bridges the gap: biologic-level outcomes at a petroleum-level price—billable, scalable, and ready today. iuvoCare connects patients with the care they deserve, overcoming barriers to access.

Key takeaway: We democratize advanced wound care at the point of need.

Meet Veris™ | Meet iuvoCare

Veris™: Advanced Wound Care Innovation

  • Bioengineered collagen-manuka matrix (99.99% MRSA kill @ clinical dose)
  • Shelf-stable ≥ 24 months
  • Ready-to-use dressing
  • Available in 1×1" & 2×2" sizes
  • U.S.-sourced raw materials (with NZ honey stockpiled)
  • Dual CMO lines (OH & TX) ensure supply
  • FDA 510(k)-exempt, CE-cleared
  • Provisional CPT Axxxx pending

iuvoCare: Purpose-Driven Innovation Vehicle in Healthcare

At iuvoCare, we believe progress begins with compassion. We are dedicated to powering care that advances medicine, delivering breakthrough therapies and daily essentials to those who need them most.

With decades of experience and a growing team of experienced, well-trained sales professionals, we take pride in connecting practitioners with crucial tools that ultimately benefit their patients.

Executive Team Summary

David Coppins, former CEO and current Executive Chairman of IntelyCare, brings a proven track record of scaling healthcare technology ventures, having revolutionized the post-acute care staffing market through AI-driven workforce solutions that now serve hundreds of facilities nationwide. Prior to IntelyCare, he led global growth at Virgin Pulse under Sir Richard Branson, where he oversaw operations, customer success, and member engagement for one of the world’s top SaaS-based wellness platforms. With decades of experience across private equity, consulting, and startups—including co-founding Upromise—Coppins is a visionary leader whose expertise in technology, scale, and healthcare makes iuvoCare a trusted growth partner.

David Coppins/CEO

Brett Walters/CTO

Brett is an experienced business leader with a proven track record. He co-founded Crocs and held senior roles at leading hospitality and real estate companies, including Director at Wyndham Destinations, Company Owner at KB Development, and Area VP of Sales at Diamond Resorts. Brett's diverse background in sales, operations, and entrepreneurship uniquely positions him to drive innovation and growth.

Jim Nelson/COO

Jim is a seasoned healthcare executive with leadership roles at iuvoCare, Craft, and Payodoc. He has driven innovation in wound care, biologics, and patient access. Jim's expertise spans clinical operations, tech-enabled care, and growth strategy.

M. Sean Agnew/CGO

Sean Agnew, the powerhouse behind iuvoCare's exponential growth in healthcare sales, has achieved success in various fields such as telecom, software, hospitality, and finance and healthcare. He has been a senior leader and even founder/CEO throughout his career. With a track record of driving double-digit growth and a remarkable 98% reorder rate, he has positively impacted over 150,000 patients nationwide.

Curtis Platt/CMO

Curtis is a serial entrepreneur and growth strategist with a proven track record of scaling high-impact companies across telecom, tech, energy, and healthcare. As co-founder of KNOK and Smart Haven, he built Canada’s top-performing TELUS dealership, while also launching Lealzy—an innovative loyalty platform backed by Grant Cardone and Jared Yellin. Now leading marketing at iuvoCare, Curtis brings cross-industry expertise, bold vision, and executional excellence to accelerate the adoption of regenerative medical solutions nationwide.

Partnership Model Overview

1

Bulk-to-Clinic / DPC (PRIMARY)

SweetBio → clinics (cartons of 15 units) → clinic bills payer or charges patient $30/unit → Company earns $10/unit.

2

Hospital-Owned DME (SECONDARY)

SweetBio → hospital DME → internal billing, with a price-tier discount ($18–$20).

3

3PL / National DME (TERTIARY)

Only for legacy accounts; limited margin, no company commission focus.

No direct-to-patient shipments from SweetBio, which protects margin and operational bandwidth.

Sample Strategy 2.0

Objectives

  1. Accelerate adoption without conditioning clinicians to a "free forever" mindset.
  1. Capture real-world data for January 2026 CMS & scaling.
  1. Reward high-value behavior (case sharing, volume, data).

Tactics

Tiered Sample Kits (co-branded flyer + 1×1″ + 2×2″)

  • Interest tier: 1 kit per clinic (awareness)
  • Pilot tier: Box of 15 units → capped at 12 priority clinics (data providers)
  • Companies receive 5–15 kits per quarter + digital flyer with personalized QR (tracks attribution).
  • "Earned Samples" portal: clinicians log 10 cases ➜ auto-ship next box; Sunshine-compliant.

Compelling Value Proposition

Training & Support Ecosystem

1

Virtual In-Services

15/30/60-min blocks (Isaac's calendar)

2

Clinician Council

Podiatry, derm, ortho, neuro, WOCN experts

3

24-h Support SLA

Via chat/email; "Carvana-style" self-service sample + case upload portal

4

Marketing Resources

Co-branded flyer (company QR) + postcard insert for sample kits

Data Feedback Loop

Data Collection

Each pilot clinic signs a Data-Share LOI (de-identified outcomes, photos, billing codes used).

Security & Compliance

SweetBio provides a RedCap form and HIPAA BAA.

Analysis & Planning

The KPI dashboard is reviewed monthly; this informs scale and CMO trigger.

Logistics & Capacity

30k

Units/Month

Current output

50k+

Units/Month

Surge capacity (single line)

600k

Units/Year

With 2nd production line

  • 11 additional machines available at TX CMO (lead-time 8 weeks) → 1.2M units/year
  • FedEx Memphis hub = 24–48h US delivery
  • Cost $12/carton (≤15 units)
  • Ready for immediate, exclusive expansion into Australia

Economic Model & Commission

One 100-patient clinic nets $30k/mo company earnings + $30k/mo iuvoCare GP.

Marketing & Awareness

  • Social drip (LinkedIn, DPC FB groups)
  • Geo-targeted paid ads per pilot city
  • Thought-leadership webinar each month (Council, KOL, CME)
  • Company lead-gen bundle in Canva

Just as a locomotive needs the right track to reach its destination, our marketing and sales strategy precisely directs Veris™ to the right healthcare providers and patients.

Risk, Compliance & Capacity Triggers

Supply Chain Security

Dual-source CMOs + 4-week safety stock; Line-2 PO issued when monthly demand exceeds 35k

Regulatory Compliance

Sunshine Act & Anti-Kickback checks on sample/commission plan

Data Security

HIPAA-compliant data capture; ISO-13485 supplier audits

Target Market Focus

Dermatologists

Sales Opportunity: Chronic wounds, skin grafts

Key Needs: Reimbursable products, fast delivery

Sales Leverage: Clinical education, sampling

MOHS Surgeons

Sales Opportunity: Post-excision reconstruction

Key Needs: Wound closure options, DME services

Sales Leverage: Bundle biologics + support

Wound Care Nurses/Practitioners

Sales Opportunity: SNFs, clinics, home health

Key Needs: Products that bill cleanly via CMS

Sales Leverage: iuvoCare billing + training

iuvoCare's team is already operating in these domains, with playbooks and reimbursement guides tailored for each specialty.

Geographic Phased Roll-out (90 Days)

1

Phase 1 Pilot (Weeks 1-4)

  • 6 DPC clusters (Las Vegas-Henderson NV, Orlando FL, Tulsa OK, Greenwood SC, Bowling Green Ky, Hawaii + (Australia/Canada) possible
  • 12 priority clinics × 15-unit boxes = 180 units (samples)
  • Target 250 patients ➜ 7,500 units commercial
2

Phase 2 Expansion (Weeks 5-8)

  • +10 clinics
  • Open hospital-DME pilots (Orlando Health Launch)
  • Scale to 20K units/month
3

Phase 3 National (Weeks 9-12)

  • Enable full iuvoCare field (box + flyer kit)
  • Legacy McKesson stream
  • Australia exclusive launch

Unlocking Patient Reach with iuvoCare

1

Initial Impact (30 Days)

Leveraging existing partnerships with SNFs, clinics, and mobile providers, we project reaching 200+ new patients in the first month through targeted pilot programs.

2

Accelerated Growth (60-90 Days)

With national infrastructure in place and scaled training, our reach expands to impact 5,000+ new patients, capturing vital real-world data for future growth.

3

National Scale (120+ Days)

Full activation of the iuvoCare network will unlock high-volume patient access, positioning Veris™ to reach 250,000+ new patients annually, driving significant data and revenue.

KPIs & Success Metrics

Addressing Core Stakeholder Concerns

Cost-Effective Market Expansion through Partnership

Building an Internal Sales Force (50-75 Reps)

Partnership with iuvoCare Advantages

  • Speed to Market: Immediate deployment across national territories
  • Cost Efficiency: Pay-for-performance model avoids upfront CapEx
  • Specialized Team: Experts in wound care, biologics, DME billing
  • Integrated 3PL & DME: Distribution and billing infrastructure included
  • Coverage Flexibility: Scale across hospitals, DPCs, clinics, SNFs
  • Existing Relationships: Reps already engaging key specialists

Time to revenue: <30 days vs. 4-6 months for internal team

Blended Equity Rollout

SweetBio + iuvoCare Strategic Partnership

Initial Equity Swap

  • iuvoCare deploys national sales force, saving SweetBio $400K–$600K cash.
  • SweetBio grants 2%–3% upfront equity (based on $20M valuation).
  • Equity: Preferred or non-voting common (optional 1-year cliff, 2-year vest).

Performance-Based Earnout

After 6–9 months, transition to performance-based equity:

  • +0.5% for 1,000 Veris kits sold
  • +0.5% at $1M revenue
  • +0.5% for 3+ health systems onboarded
  • +0.5% for CPT submission/progress

Total Earnout Potential

Max additional 2%–3% equity based on key performance milestones.

This model aligns our mutual success for accelerated market traction.

We are positioned to:

  • Launch Veris™ with immediate impact in target markets
  • Expand exclusively into Australia immediately
  • Leverage existing relationships with key healthcare providers including nationwide DPC network
  • Deliver significant ROI through our partnership model

Next 11-Day Action Items

1

Pricing Finalization

Confirm $20 clinic price and company $10 unit delta.

2

Pilot Clinic LOIs

iuvoCare growth team to secure 12 sites.

3

500 Sample Kits

SweetBio ops to assemble (including co-branded flyer and QR).

4

Earned Sample Portal

Legal to draft T&Cs; IT to configure RedCap form.

5

Board Proposal Deck

iuvoCare to confirm and execute agreement on equity/commission model with SweetBio signatories (by Thursday, July 31st).

Call to Action

Approve Launch Plan by 24 July 2025 → Kick off shipping/delivery 1 Aug 2025

"Because every wound deserves a sweeter outcome."

Contacts

Kayla Graff — CEO, SweetBio
kayla@sweetbio.com

Sean Agnew — SVP Growth, iuvocare

sean@iuvocare.com

Made with